We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

184 hedge funds and large institutions have $1.36B invested in Arcus Biosciences in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 81 increasing their positions, 54 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

50% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 54

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

6% more funds holding

Funds holding: 173 → 184 (+11)

3% more capital invested

Capital invested by funds: $1.33B → $1.36B (+$35.9M)

0.4% less ownership

Funds ownership: 73.13% → 72.73% (-0.4%)

11% less call options, than puts

Call options by funds: $4.87M | Put options by funds: $5.46M

Holders
184
Holders Change
+11
Holders Change %
+6.36%
% of All Funds
3.17%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.1%
New
26
Increased
81
Reduced
54
Closed
15
Calls
$4.87M
Puts
$5.46M
Net Calls
-$588K
Net Calls Change
+$10.7M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.3M
2
PA
Perceptive Advisors
New York
+$17.6M
3
SI
Sofinnova Investments
California
+$10.1M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$9.5M
5
O
OrbiMed
New York
+$8.01M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$32.9M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$11.2M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$10.3M
4
State Street
State Street
Massachusetts
-$7.77M
5
Morgan Stanley
Morgan Stanley
New York
-$6.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACP
176
Acuta Capital Partners
California
– -$4.24M -167,500 Closed
BCPEMI
177
Bain Capital Public Equity Management II
Massachusetts
– -$3.77M -148,887 Closed
Capital Fund Management (CFM)
178
Capital Fund Management (CFM)
France
– -$2.44M -96,224 Closed
QC
179
Quantedge Capital
Singapore
– -$1M -39,600 Closed
SG Americas Securities
180
SG Americas Securities
New York
– -$952K -37,557 Closed
HF
181
HRT Financial
New York
– -$878K -34,674 Closed
BCM
182
Bayesian Capital Management
New York
– -$348K -13,736 Closed
GC
183
Guggenheim Capital
Illinois
– -$251K -9,903 Closed
GCP
184
GSA Capital Partners
United Kingdom
– -$251K -9,888 Closed
TI
185
Trexquant Investment
Connecticut
– -$208K -8,190 Closed
CAPTRUST Financial Advisors
186
CAPTRUST Financial Advisors
North Carolina
– -$53K -2,072 Closed
SOW
187
State of Wyoming
Wyoming
– -$41K -1,611 Closed
LC
188
Lindbrook Capital
California
– -$1K -59 Closed
MAM
189
Meeder Asset Management
Ohio
– -$476 -18 -60%
C
190
Covestor
United Kingdom
– -$26 -1 -10%
VCM
191
Versant Capital Management
Arizona
– -$26 -1 -8%
DI
192
Disciplined Investments
Oklahoma
– +$53 +2 +100%
SC
193
Schubert & Co
Texas
– +$53 +2 +13%
TWA
194
TCI Wealth Advisors
Arizona
– +$53 +2 New
SIC
195
SJS Investment Consulting
Ohio
– +$79 +3 New
JWA
196
JFS Wealth Advisors
Pennsylvania
– +$212 +8 +400%
S
197
SignatureFD
Georgia
– +$344 +13 New
4 5 6 7
8

RCUS Hedge Fund Activity: Q3 2022 in Review

184 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2022, worth a combined $1.36B — up 2.7% from $1.33B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new RCUS positions and 15 closed out — a net gain of 11 holders — while 81 added to existing stakes and 54 trimmed.

The largest buyer was BlackRock, adding an estimated $21.3M. The largest seller was BVF Inc, cutting an estimated $32.9M.

  • 184 institutional investors held Arcus Biosciences (RCUS) as of Q3 2022, up from 173 in Q2 2022.
  • Funds reported $1.36B of Arcus Biosciences stock for Q3 2022, up 2.7% quarter-over-quarter.
  • 26 funds opened new Arcus Biosciences positions in Q3 2022 and 15 closed out, a net change of +11 holders.
  • The largest Arcus Biosciences buyer in Q3 2022 was BlackRock, an estimated $21.3M added.
  • The largest Arcus Biosciences seller in Q3 2022 was BVF Inc, an estimated $32.9M sold.

Based on aggregated 13F filings for Q3 2022.